+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pet Cancer Therapeutics Market - By Route Of Administration, By Species Type, and By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 - 2026

  • ID: 5144013
  • Report
  • July 2020
  • Region: Global
  • 110 pages
  • Zion Market Research
The global Pet Cancer Therapeutics market, which accrued proceeds worth 200.36 (USD Million) in 2019, is set to record the CAGR of nearly 10.7% over the period from 2020 to 2026. The report offers assessment and analysis of the Pet Cancer Therapeutics market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, sales estimates, opportunities, evolving trends, and industry-validated data. The report offers historical data from 2017 to 2019 along with a forecast from 2020 to 2026 based on revenue (USD Million).

Introduction

Pet cancer therapeutics are new anti-cancer medicine having capacity for reducing the negative impact of cancer tissues. In addition to this, pet cancer therapeutics encompass combination therapy as well as monotherapy. Apparently, the current research activities mainly focusses on proliferation of new anti-cancer medicines for enhancing efficiency and minimizing treatment side-effects.

Market Growth Dynamics

Growing trend of adopting pets like cats & dogs across the globe will promote the expansion of pet cancer therapeutics industry over the forecast timeline. Increase in the occurrence of pet cancer in the developed nations will proliferate the pet cancer therapeutics market progression in the years to come. Additionally, a surge in the pet populace in the countries like the U.S., UK, and Germany will culminate in humungous market demand over the estimated timespan.

Furthermore, rise in the awareness about the pet ailments along with rise in tendency towards spending on pet care as well as treatment of pets will exponentiate the growth of the pet cancer therapeutics industry over the forecasting years. Additionally, rise in various kinds of cancers in dogs & cats and surge in the funding of research activities pertaining to cancer therapy in canines & cats will prompt the business growth over the span of next few years.

North America To Account For Major Market Share Over 2020-2026

The growth of the market in the North American sub-continent over the forecast timeline is due to huge presence of reputed industry participants in the countries like the U.S. and the UK. Additionally, a large-scale product penetration as well as product innovation to effectively treat various kinds of pet cancers will elevate the market growth over the estimated timeline.

Key players influencing the market growth include Karyopharm Therapeutics, Inc., Zoetis, Oasmia Pharmaceuticals AB, Zenoaq, AB Science, Aratana Therapeutics, Inc., Rhizen Pharmaceuticals SA, Morphogenesis, Inc., Boehringer Ingelheim International GmbH, Regeneus Ltd., and VetDC, Inc.

The global pet cancer therapeutics market is segmented as follows:

By Route of Administration
  • Parenteral
  • Oral
  • Others
By Cancer type
  • Melanoma
  • Lymphoma
  • Mammary & squamous cell cancer
  • Mast cell cancer
  • Others
By species type
  • Cat
  • Dog
  • Others
By Region
  • North America
  • The U.S.
  • Canada
  • Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa
Note: Product cover images may vary from those shown
  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Pet Cancer Therapeutics Market, 2016–2026(USD Million)
    • 2.2. Pet Cancer Therapeutics Market: Snapshot
  • Chapter 3. Global Pet Cancer Therapeutics Market– Industry Analysis
    • 3.1. Pet Cancer Therapeutics Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Growing trend of adopting pets like cats & dogs across the globe will promote the expansion of pet cancer therapeutics industry over the forecast timeline.
      • 3.2.2. Increase in the occurrence of pet cancer in the developed nations will pruliferate the pet cancer therapeutics market progression in the years to come.
    • 3.3. Market Attractiveness Analysis
      • 3.3.1. Market attractiveness analysis By Route Of Administration
      • 3.3.2. Market attractiveness analysis By Cancer Type
      • 3.3.3. Market attractiveness analysis By Species Type
  • Chapter 4. Global Pet Cancer Therapeutics Market– Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Pet Cancer Therapeutics Market: company market share, 2019
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product Type launches
      • 4.2.3. Agreements, partnerships, collaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Pet Cancer Therapeutics Market– By Route Of Administration Analysis
    • 5.1. Global Pet Cancer Therapeutics Market overview: By Route Of Administration
      • 5.1.1. Global Pet Cancer Therapeutics Market share, By Route Of Administration ,2019 and 2026
    • 5.2. Parenteral
      • 5.2.1. Global Pet Cancer Therapeutics Market by Parenteral, 2016–2026(USD Million)
    • 5.3. Oral
      • 5.3.1. Global Pet Cancer Therapeutics Market by Oral, 2016–2026(USD Million)
    • 5.4. Others
      • 5.4.1. Global Pet Cancer Therapeutics Market by Others, 2016–2026(USD Million)
  • Chapter 6. Global Milk Packaging Market– Cancer Type Analysis
    • 6.1. Global Pet Cancer Therapeutics Market overview: By Cancer Type
      • 6.1.1. Global Pet Cancer Therapeutics Market share, By Cancer Type , 2019 and 2026
    • 6.2. Melanoma
      • 6.2.1. Global Pet Cancer Therapeutics Market By Melanoma, 2016–2026(USD Million)
    • 6.3. Mast Cell Cancer
      • 6.3.1. Global Pet Cancer Therapeutics Market By Mast Cell Cancer, 2016–2026(USD Million)
    • 6.4. Lymphoma
      • 6.4.1. Global Pet Cancer Therapeutics Market By Lymphoma, 2016–2026(USD Million)
    • 6.5. Mammary & Squamous Cell Cancer
      • 6.5.1. Global Pet Cancer Therapeutics Market By Mammary & Squamous Cell Cancer, 2016–2026(USD Million)
    • 6.6. Others
      • 6.6.1. Global Pet Cancer Therapeutics Market By Others, 2016–2026(USD Million)
  • Chapter 7. Global Milk Packaging Market– Species Type Analysis
    • 7.1. Global Pet Cancer Therapeutics Market overview: By Species Type
      • 7.1.1. Global Pet Cancer Therapeutics Market share, By Species Type, 2019 and 2026
    • 7.2. Cat
      • 7.2.1. Global Pet Cancer Therapeutics Market By Cat, 2016–2026(USD Million)
    • 7.3. Dog
      • 7.3.1. Global Pet Cancer Therapeutics Market By Dog, 2016–2026(USD Million)
    • 7.4. Others
      • 7.4.1. Global Pet Cancer Therapeutics Market By Others, 2016–2026(USD Million)
  • Chapter 8. Company Profiles
    • 8.1. Aratana Therapeutics, Inc.
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Product Portfolio
      • 8.1.4. Business Strategy
      • 8.1.5. Recent Developments
    • 8.2. Oasmia Pharmaceuticals AB
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Product Portfolio
      • 8.2.4. Business Strategy
      • 8.2.5. Recent Developments
    • 8.3. Zenoaq
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Product Portfolio
      • 8.3.4. Business Strategy
      • 8.3.5. Recent Developments
    • 8.4. AB Science
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Product Portfolio
      • 8.4.4. Business Strategy
      • 8.4.5. Recent Developments
    • 8.5. Rhizen Pharmaceuticals SA
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Product Portfolio
      • 8.5.4. Business Strategy
      • 8.5.5. Recent Development
    • 8.6. Rhizen Pharmaceuticals SA
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Product Portfolio
      • 8.6.4. Business Strategy
      • 8.6.5. Recent Development
    • 8.7. Morphogenesis, Inc.
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Product Portfolio
      • 8.7.4. Business Strategy
      • 8.7.5. Recent Development
    • 8.8. Karyopharm Therapeutics, Inc.
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Product Portfolio
      • 8.8.4. Business Strategy
      • 8.8.5. Recent Development
    • 8.9. Boehringer Ingelheim International GmbH
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Product Portfolio
      • 8.9.4. Business Strategy
      • 8.9.5. Recent Development
    • 8.10. Regeneus Ltd.
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. Product Portfolio
      • 8.10.4. Business Strategy
      • 8.10.5. Recent Development
    • 8.11. Zoetis
      • 8.11.1. Overview
      • 8.11.2. Financials
      • 8.11.3. Product Portfolio
      • 8.11.4. Business Strategy
      • 8.11.5. Recent Development
    • 8.12. VetDC, Inc.
      • 8.12.1. Overview
      • 8.12.2. Financials
      • 8.12.3. Product Portfolio
      • 8.12.4. Business Strategy
      • 8.12.5. Recent Development
Note: Product cover images may vary from those shown
Adroll
adroll